KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Payables: 2020-2025

Historic Payables for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $53.1 million.

  • AbCellera Biologics' Payables fell 1.22% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.0 million, marking a year-over-year increase of 8.33%. This contributed to the annual value of $55.0 million for FY2024, which is 10.94% up from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Payables is $53.1 million, which was up 6.08% from $50.1 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Payables ranged from a high of $55.0 million in Q4 2024 and a low of $13.3 million during Q1 2021.
  • In the last 3 years, AbCellera Biologics' Payables had a median value of $49.6 million in 2023 and averaged $46.9 million.
  • In the last 5 years, AbCellera Biologics' Payables spiked by 114.82% in 2023 and then dropped by 16.11% in 2024.
  • AbCellera Biologics' Payables (Quarterly) stood at $32.0 million in 2021, then spiked by 63.97% to $52.5 million in 2022, then decreased by 5.56% to $49.6 million in 2023, then grew by 10.94% to $55.0 million in 2024, then fell by 1.22% to $53.1 million in 2025.
  • Its last three reported values are $53.1 million in Q3 2025, $50.1 million for Q2 2025, and $47.8 million during Q1 2025.